Topics covered in this report range from the successes of Turkey’s Healthcare Transformation Programme (HTP), which has skyrocketed the level of the country’s healthcare system in little over a decade, the ongoing debate around reimbursement, and a localization policy to which multinational companies are having to adapt.
Other hot-button issues touched upon include Turkey’s standing as the world’s third largest medical tourism market, the domestic companies increasingly looking to export their Turkish-made products, the government’s ambitious proposal to transform the country into a biotech hub by 2020, and the nation’s burgeoning reputation as a clinical trials destination.
Through the exclusive insights of policymakers, the heads of local pharma champions as well as multinational affiliate leaders, a picture emerges of Turkey as a country facing significant challenges – not least in terms of the devaluation of the Turkish lira – but one finally moving towards creating a regulatory and economic environment that is conducive to further growth.
Click here to download Healthcare & Life Sciences Review: Turkey 2019.